Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Organogenesis Holdings Inc. (ORGO)

New York, New York--(Newsfile Corp. - October 9, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Organogenesis Holdings Inc. ("Organogenesis Holdings Inc.") (NASDAQ: ORGO) concerning possible violations of federal securities laws.

Organogenesis issued a press release on September 25, 2025, disclosing that a second phase 3 trial of its cryopreserved amniotic suspension allograft ReNu missed its primary endpoint, having failed to achieve a significantly significant change in pain reduction. The Company said it would ask for a pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration by the end of October to examine a submission pathway, "including using the combined efficacy analysis from both Phase 3 studies to support a BLA approval," according to Chief Operating Officer Patrick Bilbo.

Following this news, Organogenesis's stock price fell over 12% on September 26, 2025. To obtain additional information, go to:

https://zlk.com/pslra-1/organogenesis-holdings-inc-lawsuit-submission-form?prid=171531&wire=5&utm_campaign=57

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269902